• Home >
  • Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe

Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe

17-Jul-2015  /  Research Code: D757-00-03-00-00  /  SKU: HC02733-GL-TA_19627  /  
Region: Global

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles a drug for oculopharyngeal muscular dystrophy treatment that receives orphan drug designation; non-viral CFTR-based gene therapy for cystic fibrosis patients, a breast cancer diagnostic test in Europe.

Table of Contents

Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in EuropeIn This Issue1. DRUG FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY TREATMENT RECEIVES ORPHAN DRUG DESIGNATION2. NON-VIRAL CFTR-BASED GENE THERAPY FOR CYSTIC FIBROSIS PATIENTS3. BREAST CANCER DIAGNOSTIC TEST IN EUROPE4. RECENT PATENTS IN GENETIC TESTS IN THE EUROPEAN UNION5. TECHVISION 2015




Related Research

Recent Advances in Cancer Immunotherapy and Tumor Profiling Technologies

Release Date : 19-May-17

Region : Global

Innovations in Medical Device Technologies

Release Date : 19-May-17

Region : Global

Advancements across Health and Wellness

Release Date : 12-May-17

Region : Global

Therapeutic Breakthroughs in Multiple Sclerosis

Release Date : 12-May-17

Region : Global

Bioinformatics and Advanced Analytics Powering Drug Discovery

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Vision & Strategy

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Brand & Demand

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Technology & IP

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

Global Prespective

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.